异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究*

doi:10.3969/j.issn.1672-5069.2022.03.017

摘要/Abstract

摘要： 目的分析比较异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤(DILI)患者的疗效。方法 2018年1月～2020年1月我院收治的DILI患者102例,随机分为观察组51例和对照组51例,分别给予异甘草酸镁或复方甘草酸单胺静脉滴注治疗14～28 d。采用放射免疫法检测层粘连蛋白(LN)、透明质酸酶(HA)、III型前胶原(PC-III)和IV型胶原(IV-Col)水平,采用ELISA法检测超氧化物歧化酶(SOD)、一氧化氮(NO)、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)。结果治疗后,观察组血清ALT和AST水平分别为(42.7±12.5)U/L和(38.2±9.4)U/L,显著低于对照组【分别为(64.5±21.9)U/L和(55.6±15.2)U/L, P＜0.05】;血清HA、PC-III和IV-Col水平分别为(138.2±21.5)mg/L、(85.6±17.4)μg/L和(141.5±16.4)μg/L,显著低于对照组【分别为(182.1±23.9)mg/L、(123.8±19.4)μg/L和(175.4±18.7)μg/L,P＜0.05】;血清SOD和NO水平分别为(90.3±10.1)U/L和(79.8±9.3)μmol/L,显著高于对照组【分别为(74.9±8.6)U/L和(54.0±7.9)μmol/L,P＜0.05】,而血清IL-6和TNF-α水平分别为(11.2±2.5)pg/mL和(26.4±3.6)ng/L,显著低于对照组【分别为(16.8±2.7)pg/mL和(41.3±5.9)ng/L,P＜0.05】。结论应用异甘草酸镁治疗DILI患者临床疗效优于复方甘草酸单胺,可有效改善血生化指标和肝纤维化指标,可能与减轻了机体氧化应激和炎症反应有关。

关键词: 药物性肝损伤, 异甘草酸镁, 复方甘草酸单胺, 氧化应激, 治疗

Abstract: Objective The aim of this study was to compare the therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury (DILI). Methods A total of 102 patients with DILI were enrolled in our hospital between January 2018 and January 2020, and were randomly divided into observation and control group, with 51 cases in each group. The patients in the observation were treated by intravenous administration of magnesium isoglycyrrhizinate, those in the control were treated by intravenous compound glycyrrhizin monoamine, and the regimen lasted for 14 to 28 days. Serum laminin (LN), hyaluronidase (HA), procollagen-III (PC-III) and collage type IV (IV-Col) were detected by radioimmunoassay. Serum superoxide dismutase (SOD), nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected by ELISA. Results At the end of the treatment, serum ALT and AST levels in the observation group were (42.7±12.5)U/L and (38.2±9.4)U/L, both significantly lower than [(64.5±21.9)U/L and (55.6±15.2)U/L, respectively, P＜0.05] in the control; serum HA, PC-III and IV-Col levels were (138.2±21.5)mg/L, (85.6±17.4)μg/L and (141.5±16.4)μg/L, all significantly lower than [(182.1±23.9)mg/L, (123.8±19.4)μg/L and (175.4±18.7)μg/L, respectively, P＜0.05]; serum SOD and NO levels were (90.3±10.1)U/L and (79.8±9.3)μmol/L, both significantly higher than [(74.9±8.6)U/L and (54.0±7.9)μmol/L, respectively, P＜0.05], while serum IL-6 and TNF-α levels were (11.2±2.5)pg/mL and (26.4±3.6)ng/L, both significantly lower than [(16.8±2.7)pg/mL and (41.3±5.9) ng/L, respectively, P＜0.05] in the control. Conclusion The therapeutic efficacy of magnesum isoglycyrrhizinate is promising in dealing with patients with DILI, which could effectively improve serum biochemical indexes normal and alleviate oxidative stress.

Key words: Drug-induced liver injury, Magnesium isoglycyrrhizinate, Compound glycyrrhizin monoamine, Oxidative stress, Therapy

陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 371-374.

Chen Yejing, Lu Qingping, Gu Shaoying. Comparison of therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2022, 25(3): 371-374.

参考文献

[1] European Association for the Study of the Liver. EAsl clinical practice guidelines: drug-induced liver injury. J Hepatol, 2019,70(6):1222-1261.
[2] Andrade RJ, Chalasani N, Bjornsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers, 2019,5(1):58.
[3] Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med, 2019,18(3):264-273.
[4] McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury. Adv Pharmacol, 2019,8(5):221-239.
[5] Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis, 2019,20(3):122-126.
[6] Devarbhavi H, Raj S. Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver Int, 2019,39(5):802-811.
[7] 黄春洋,单晶,廖慧钰,等. 甲基强的松龙治疗DILI患者临床及实验室特点分析. 实用肝脏病杂志, 2019, 22(2):208-211.
[8] Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, et al. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res, 2021,16(4):105.
[9] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23(11):810-820.
[10] 余曦,杨蓉蓉. 药物性肝损伤384例临床分析. 中华全科医师杂志, 2020, 19(4):340-344.
[11] Hoofnagle JH, Björnsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med,2019,18(3):264-273.
[12] Roth RA, Ganey PE. What have we learned from animal models of idiosyncratic, drug-induced liver injury? Expert Opin Drug Metab Toxicol,2020,16(6):475-491.
[13] Andrade RJ, Robles-Díaz M. Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. Liver Int, 2020,40(1):6-17.
[14] 刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点. 实用肝脏病杂志, 2019, 22(2):14-17.
[15] 吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨. 实用肝脏病杂志, 2019, 22(2):212-215.
[16] 詹爱琴,陈春丽,朱庆峰,等. 异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化. 实用肝脏病杂志, 2020,23(6):793-796.
[17] 周炎仪,阳灿. 雷公藤多甙片联合异甘草酸镁治疗自身免疫性肝炎患者疗效初步研究. 实用肝脏病杂志, 2019, 22(3):365-368.
[18] 吴玲玲,王玮,王亚东,等. 反复肝功能异常伴发热及肾功能异常DILI一例. 中华全科医师杂志, 2019, 18(11):1098-1100.
[19] Andrade RJ, Robles-Díaz M. Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. Liver Int,2020,40(1):6-17.
[20] Church RJ, Watkins PB. Serum biomarkers of drug-induced liver injury: Current status and future directions. J Dig Dis, 2019,20(1):2-10.
[21] Yang YZ, Liu ZH, Wang SC,et al. Magnesium isoglycyrrhizinate alleviates fructose-induced liver oxidative stress and inflammatory injury through suppressing NOXs. Eur J Pharmacol, 2020,15(3):173-175.
[22] Wang M, Liu CY, Wang T, et al. (+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis. Cell Death Dis, 2020,11(9):781-783.
[23] 杜颖,姜志红,吴雅玲. 雷公藤多甙联合异甘草酸镁治疗儿童自身免疫性肝炎疗效及其对血清IL-17和CXCL10水平的影响. 实用肝脏病杂志, 2020, 23(3):50-53.
[24] Zhao Z, Liu M, Zhang Y, et al. Cardioprotective effect of monoammonium glycyrrhizinate injection against myocardial ischemic injury in vivo and in vitro: involvement of inhibiting oxidative stress and regulating ca²⁺ homeostasis by l-type calcium channels. Drug Des Devel Ther,2020,3(14):331-346.
[25] Chu S, Niu Z, Guo Q, et al. Combination of monoammonium glycyrrhizinate and cysteine hydrochloride ameliorated lipopolysaccharide/galactosamine-induced acute liver injury through Nrf2/ARE pathway. Eur J Pharmacol, 2020,5(2):18-19.
[26] 李银玲,翁丽媚,吴思思,等. 药物性肝损伤时肾生物化学指标的改变及其临床意义. 中华肝脏病杂志, 2019, 27(2):143-145.
[27] 林成, 王同彪, 李岳勇,等. 甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗药物性肝损伤患者疗效研究. 实用肝脏病杂志, 2021, 24(2):232-235.

异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*

Comparison of therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[3]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[4]	柴晓哲, 朱霞峰, 骆成林, 王少峰. 泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 355-358.
[5]	胡春霞, 杨娇楠, 张丰晓, 胡敬华. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 359-362.
[6]	杨海华, 周聪, 沈国强, 尤晓红, 孟玲. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志, 2022, 25(3): 375-378.
[7]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[8]	沈扬林, 谭可平, 游忠岚, 陈婵, 陆晖, 甘琼萍, 覃国琦, 陆鹏. 血浆置换序贯双重血浆分子吸附系统治疗慢加急性乙型肝炎肝衰竭患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 387-390.
[9]	孙亚男, 曾庆环, 刘远志, 张世斌, 李鹏, 武永乐, 丁惠国. 伴有中/重度食管静脉曲张的慢加急性肝衰竭患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 391-394.
[10]	詹惠珍, 杜雅钦, 王松姣. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 395-398.
[11]	郭慧雯, 张峰, 肖江强, 张玮, 张明, 邹晓平, 诸葛宇征. 球囊导管闭塞下逆行性静脉栓塞术治疗胃静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 407-410.
[12]	邱云, 杨玫, 薛红红. TACE联合超声引导下微波消融治疗特殊部位原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 419-422.
[13]	马虎成, 任昊桢, 汤宁, 王帅, 张玉衡, 施晓雷. 机器人与开腹手术治疗肝内胆管细胞癌患者近期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 423-426.
[14]	江攀, 张惠林, 刘海, 苏娟. 超声引导下穿刺硬化治疗肝肾囊肿患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 439-442.
[15]	孙皆齐, 姜绍文, 汪铮. 应用艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎初治和经治患者效果对比研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 195-198.